Sign up


Match Document Document Title
8999966 Compounds that are ERK inhibitors  
Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl...
8999968 Kinase inhibitors and method of treating cancer with same  
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase...
9000175 Bicyclic GPR119 modulators  
The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of...
8999957 Heterocyclic compounds as ERK inhibitors  
The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as...
8993589 Imidazopyridine derivatives which inhibit the secretion of gastric acid  
The present invention relates to substituted imidazo [1,2-a]pyridines of formula I where R is —CH2COOH or —COOH, which inhibits exogenously or endogenously stimulated gastric acid secretion and can...
8993564 7-azaindole derivatives suitable for treatment of cancers  
Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed treatment of tumours.
8993590 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders  
The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates...
8993779 Positive allosteric modulators of MGLUR2  
The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and...
8993612 Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer  
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The...
8987297 Nitrogen containing compounds  
Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed.
8987250 Therapeutic compounds  
Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds d...
8981101 7-azaindole derivatives  
Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of...
8980911 Heterocyclic compounds as protein kinase inhibitors  
The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R1, R2 and R3 are as d...
8980887 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof  
Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates,...
8980910 Treatment of glaucoma  
A method is provided for treating patients suffering from elevated intraocular pressure or fluctuation in intraocular pressure, including for example glaucoma patients. The method comprises...
8980895 AMPK modulators  
The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes,...
8980893 Antiparisitic dihydroazole compounds and compositions comprising same  
The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R1, A1, A2, G, X and Y are as defined in the description, compositions thereof, processes for their...
8980888 Pyrazole derivative  
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative...
8975261 Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors  
The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with...
8975275 Use of chemotherapeutic agents  
The invention relates to the use of chemotherapeutic agents for the production of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans...
8975276 Inhibitors of PDE10  
PDE10 inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit PDE10 are also disclosed.
8975406 Compound useful for the treatment of degenerative and inflammatory diseases  
Novel pyrrazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prophylaxis and...
8969347 Compounds and methods for treating inflammatory and fibrotic disorders  
Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound,...
8969375 CDK9 kinase inhibitors  
Disclosed are compound of Formula (Ia), wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used...
8969570 Beta-lactamase inhibitors  
Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure p...
8969345 Dibenzooxepin derivative  
A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a...
8969334 Nitrogen containing compounds and their use  
Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.
8962650 Therapeutic agent for tumor  
A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein R1 is C1-6...
8957102 Heterocyclic compound as protein kinase inhibitor  
Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the...
8957062 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment  
Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The...
8957088 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments  
The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1...
8957066 Histone deacetylase inhibitors  
This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I), wherein the substituents are as defined herein.
8957087 Heterocyclic substituted acardite derivate and application thereof  
This present invention discloses a heterocyclic substituted acardite derivate and application thereof, namely compounds in the general formula (1) or the general formula (2) or pharmaceutically...
8952034 Fused heterocyclic compounds as ion channel modulators  
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In...
8952004 CXCR3 receptor antagonists  
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R3, A, B, X, and n are as defined herein. The invention also relates to...
8946215 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use  
The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or...
8940756 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases  
The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or...
8940742 Heterocyclic compounds and uses thereof  
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and...
8933094 Ethynyl compounds useful for treatment of CNS disorder  
The present invention relates to ethynyl compounds of formula wherein X, Y, Z, and R4 are as defined herein or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or...
8927534 Compounds for the inhibition of integrins and use thereof  
The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; Ψ is a radical of formula (II), R2 is a hydrophobic ...
8927545 Inhibiting Eph B-3 kinase  
EphB3 kinase inhibitor compounds, including certain pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine compounds, inhibit EphB3 kinase. The EphB3 kinase inhibitor compounds can have greater potency...
8921389 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase  
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia...
8916583 Therapeutic compositions for intranasal administration of zolpidem  
The invention provides sprayable aqueous compositions containing zolpidem or single stereoisomer, mixtures of stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, a solubilizing...
8916571 Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase  
The invention relates to the treatment of cancer using an inhibitor of 5′-methylthioadenosine phosphorylase (MTAP). The invention particularly relates to the treatment of prostate cancer and head a...
8912216 Hetaryl-[1,8]naphthyridine derivatives  
Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W1, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed,...
8912181 Bicyclic compound or salt thereof  
A novel bicyclic compound having an HSP90 inhibitory effect and a carcinostatic effect. A pharmaceutical agent based on the HSP90 inhibitory effect and useful in the prevention and/or treatment of...
8906392 Nanocluster compositions and methods  
Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of...
8906912 Anxiolytic compounds  
The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety...
8906923 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones  
The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further...
8906911 Chemokine receptor antagonists  
Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating...